title: Prolactin-releasing peptide stimulates catecholamine release but not proliferation in rat pheochromocytoma PC12 cells.
abstract: We examined the effect of prolactin-releasing peptide (PrRP) on catecholamine secretion and DNA synthesis in rat pheochromocytoma PC12 cells. We initially confirmed the expression of both PrRP and its receptor in PC12 cells. PrRP31 and PrRP20 (> or =10 nM) significantly increased dopamine secretion from PC12 cells. However, PrRP20-stimulated dopamine secretion was markedly weaker than that of PrRP31. Both EDTA (extracellular Ca2+ chelator) and BAPTA-AM (intracellular Ca2+ chelator) effectively suppressed PrRP31 (100 nM)-induced dopamine secretion. PrRP31and PrRP20 (> or =1 nM) significantly induced an increase in the level of cAMP. The PKA inhibitor H89 (at 10 microM) impeded PrRP31- and PrRP20-induced dopamine secretion. Finally, we confirmed that PrRP did not affect DNA synthesis. These results indicate that PrRP may regulate catecholamine secretion but not the mitogenic effects in chromaffin cells.
authors.affiliation: Department of Clinical Pathology, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki, 305-8575, Japan.
authors.forename: Toru
authors.initials: T
authors.lastname: Nanmoku
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Takekoshi
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Isobe
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Kawakami
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Nakai
authors.forename: Yukichi
authors.initials: Y
authors.lastname: Okuda
mesh_terms: D000818:Animals; D015152:Blotting, Northern; D002395:Catecholamines / Q000032:analysis / Q000378:metabolism*; D002614:Chelating Agents / Q000494:pharmacology; D000242:Cyclic AMP / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004492:Edetic Acid / Q000494:pharmacology; D004533:Egtazic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007028:Hypothalamic Hormones / Q000494:pharmacology*; D007546:Isoquinolines / Q000494:pharmacology; D009479:Neuropeptides / Q000494:pharmacology*; D009538:Nicotine / Q000494:pharmacology; D018722:Nicotinic Agonists / Q000494:pharmacology; D016716:PC12 Cells / Q000187:drug effects* / Q000378:metabolism; D010673:Pheochromocytoma / Q000473:pathology; D056690:Prolactin-Releasing Hormone; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D018013:Receptors, Neuropeptide / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D013449:Sulfonamides
chemical_list: D002395:Catecholamines; D002614:Chelating Agents; D004791:Enzyme Inhibitors; D007028:Hypothalamic Hormones; D007546:Isoquinolines; D009479:Neuropeptides; D018722:Nicotinic Agonists; C534379:Prlh protein, rat; D056690:Prolactin-Releasing Hormone; D012333:RNA, Messenger; D018013:Receptors, Neuropeptide; D013449:Sulfonamides; C400801:receptor, prolactin-releasing peptide; C070379:1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester; D004533:Egtazic Acid; D009538:Nicotine; D004492:Edetic Acid; D000242:Cyclic AMP; C063509:N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide